Spots Global Cancer Trial Database for First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer
Official Title: CORRECT-MRD I: First Colorectal Cancer Clinical Validation Study to Predict Recurrence Using a Circulating Tumor DNA Assay to Detect Minimal Residual Disease
Study ID: NCT06398743
Conditions
Interventions
Study Description
Brief Summary: The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HaEmek Medical Center, Afula, North, Israel
Hadassah Medical Center, Jerusalem, , Israel
Istituto Clinico Humanitas, Rozzano, Milano, Italy
ASST Grande Ospedale Metropolitano Niguarda, Milano, , Italy
Istituto Nazionale Tumori - Fondazione G Pascale, Napoli, , Italy
Hospital Universitario La Paz, Madrid, , Spain
Centro Integral Oncológico Clara Campal (HM CIOCC), Madrid, , Spain
Edinburgh Cancer Centre, Edinburgh, Scotland, United Kingdom
Ipswich Hospital, Ipswich, , United Kingdom
Torbay Hospital, Torquay, , United Kingdom
Contact Details
Name: Melanie Palomares, MD
Affiliation: Exact Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
